Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration
Tóm tắt
We explored the epidemiology of hypoglycaemia in individuals with insulin-treated diabetes by testing the hypothesis that diabetes type and duration of insulin treatment influence the risk of hypoglycaemia. This was an observational study over 9–12 months in six UK secondary care diabetes centres. Altogether 383 patients were involved. Patients were divided into the following three treatment groups for type 2 diabetes: (1) sulfonylureas, (2) insulin for <2 years and (3) insulin for >5 years, and into two treatment groups for type 1 diabetes, namely <5 years disease duration and >15 years disease duration. Self-reported (mild and severe) and biochemical episodes (interstitial glucose <2.2 mmol/l using continuous glucose monitoring) were recorded. Mild hypoglycaemia in type 2 diabetic patients on insulin for <2 years was less frequent than in type 1 patients with <5 years disease duration (mean rate: 4 vs 36 episodes per subject-year, p < 0.001). In type 2 diabetic patients treated with sulfonylureas or insulin for <2 years, no differences were observed in the proportion experiencing severe hypoglycaemia (7 vs 7%, difference 0 [95% CI: −7 to 9%]), mild symptomatic (39 vs 51%, difference 12 [−3 to 25%]) or interstitial glucose <2.2 mol/l (22 vs 20%, difference 2 [−13 to 10%]). Severe hypoglycaemia rates were comparable in patients with type 2 diabetes on sulfonylureas or insulin < 2 years (0.1 and 0.2 episodes per subject-year) and far less frequent than in type 1 diabetes (<5 years group, 1.1; >15 years group, 3.2.episodes per subject-year). During early insulin use in type 2 diabetes, the frequency of hypoglycaemia is generally equivalent to that observed in patients treated with sulfonylureas and considerably lower than during the first 5 years of treatment in type 1 diabetes.
Tài liệu tham khảo
Pedersen-Bjergaard U, Pramming S, Heller SR et al (2004) Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 20:479–486
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853
Gerich JE (2000) Hypoglycaemia and counterregulation in type 2 diabetes. Lancet 356:1946–1947
Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM (1993) Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 10:231–237
Leese GP, Wang J, Broomhall J et al (2003) Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26:1176–1180
Henderson JN, Allen KV, Deary IJ, Frier BM (2003) Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 20:1016–1021
Donnelly LA, Morris AD, Frier BM et al (2005) Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 22:749–755
Marshall SM, Home PD, Manley SE, Barth JH, John WG (2002) Standardization of glycated haemoglobin. Diabet Med 19:429
Deary IJ (1993) Effects of hypoglycaemia on cognitive function. In: Frier BM, Fisher BM (eds) Hypoglycaemia and diabetes. Edward Arnold, London, pp 80–92
Evans ML, Pernet A, Lomas J, Amiel SA (2000) Delay in onset of awareness of acute hypoglycemia and of restoration of cognitive performance during recovery. Diabetes Care 23:893–897
Machin D, Campbell MJ, Fayers PM, Pinol A (1997) Sample size tables for clinical studies. Blackwell, Oxford
Altman DG, Machin D, Bryant T (2000) Statistics with confidence. BMJ, London
Perneger TV (1998) What’s wrong with Bonferroni adjustments. BMJ 316:1236–1238
Gold AE, MacLeod KM, Frier BM (1994) Frequency of severe hypoglycemia in patients with type I (insulin dependent) diabetes with impaired awareness of hypoglycemia. Diabetes Care 17:697–703
Zammitt NN, Frier BM (2005) Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28:2948–2961
Pramming S, Thorsteinsson B, Bendtson I, Binder C (1991) Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 8:217–222
MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10:238–245
ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW (2000) Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 23:1467–1471
The Diabetes Control and Complications Trial Research Group (1991) Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:450–459
Bolli GB, De Feo P, Compagnucci P et al (1983) Abnormal glucose counterregulation in IDDM. Interaction of anti- insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32:134–141
Abraira C, Colwell JA, Nuttall FQ et al (1995) Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 18:1113–1123
McGowan K, Thomas W, Moran A (2002) Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. Diabetes Care 25:1499–1503
Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ (2003) Physiological differences between interstitial glucose and blood glucose measured in human subjects. Diabetes Care 26:2405–2409
Caplin NJ, O’Leary P, Bulsara M, Davis EA, Jones TW (2003) Subcutaneous glucose sensor values closely parallel blood glucose during insulin-induced hypoglycaemia. Diabet Med 20:238–241